Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Status:
Recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
For high-risk stage II and stage III colorectal cancer, even after radical resection and
postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and
metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor
immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the
effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and
stage III colorectal cancer after radical resection.